ROS as a Novel Indicator to Predict Anticancer Drug Efficacy

• DOI: 10.21203/rs.2.11911/v1
• Publication Date: 2019-07-24T20:46:13Z
• Authors: Tarek Zaidieh; James Smith; Karen Ball; Qian An
• Keywords: Mitochondrial ROS; Viability assay

Abstract Background Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) generation. Generally, cancer cells with mitochondrial genetic abnormalities (copy number change and mutations) have escalated ROS levels compared to normal cells. Since high can trigger apoptosis, treating low doses mitochondria-targeting / ROS-stimulating agents may offer cancer-specific therapy. This study aimed investigate how baseline might influence cells’ response Methods Four one cell lines were treated conventional drug (cisplatin) agent (dequalinium chloride hydrate) separately jointly. Cell viability was assessed combination synergisms indicated by the index (CI). Mitochondrial DNA copy (MtDNAcn), membrane potential (MMP) measured, relative expression genes proteins involved in ROS-mediated apoptosis pathways also investigated. Results Our data showed correlation between level, mtDNAcn sensitivity tested Synergistic effect both drugs observed being key contributor death. Conclusions findings suggest that therapy could be more effective treatments. In addition, sensitive treatment, while resistant. provides an insight into understanding on sensitivity, lead development new therapeutic strategies improve efficacy anticancer